Article Information
History
- September 9, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Sitthichai Kanokudoma,b,
- Jira Chansaenroja,
- Nungruthai Suntronwonga,
- Suvichada Assawakosria,b,
- Ritthideach Yorsaenga,
- Pornjarim Nilyanimita,
- Ratchadawan Aeemjindaa,
- Nongkanok Khanarata,
- Preeyaporn Vichaiwattanaa,
- Sirapa Klinfuenga,
- Thanunrat Thongmeea,
- Apirat Katanyutanonc,
- Wichai Thanasoponc,
- Jirawan Arayapongd,
- Withak Withaksabutc,
- Donchida Srimuana,
- Thaksaporn Thatsanatorna,
- Natthinee Sudhinaraseta,
- Nasamon Wanlapakorna,
- Sittisak Honsawekb,* and
- Yong Poovorawana,e,*
- aCenter of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand
- bCenter of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand
- cChonburi Provincial Public Health Office, Bansuan, Mueang Chonburi, Chonburi, 20000, Thailand
- dChonburi Hospital, Bansuan, Mueang Chonburi, Chonburi, 20000, Thailand
- eFRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok, 10300, Thailand
- ↵*Corresponding authors: Sittisak Honsawek (sittisak.h{at}chula.ac.th); Yong Poovorawan (yong.p{at}chula.ac.th)
Posted September 09, 2022.
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax™) after homologous and heterologous two-dose regimens
